About 50,000 people in the U.S. are diagnosed annually with head, neck, nasal and oral cancers. Most are treated with radiation, and of those, 70-80 percent develop a painful and debilitating side effect called severe oral mucositis (SOM). While some drugs are available to treat SOM once it develops, none can prevent it. But today, researchers are reporting on a new drug, called GC4419, that appears to do just that.
Although still in clinical trials, it has already been designated by the U.S. Food and Drug Administration as a “breakthrough therapy.”
“It is exciting to publicly report on the structure and synthesis of GC4419 for the first time,” says Dennis P. Riley, Ph.D., leader of the study. “We believe GC4419 has the potential to address an important unmet medical need in the treatment of cancer patients undergoing radiation therapy, and we look forward to commencing a Phase 3 trial with GC4419 in head and neck cancer patients this year.”
Oral mucositis (OM) is a painful and problematic complication during cancer treatment, especially radiation therapy, which breaks down the epithelial cells lining the mouth. Patients suffering from OM experience severe pain, inflammation, ulceration and bleeding. Most patients receiving chemoradiotherapy develop SOM, as defined by the World Health Organization as grade 3 or 4 of OM. In the most severe cases, patients can’t swallow or consume liquids or solid food, often leading to the use of feeding tubes and narcotic analgesics. Patients are also susceptible to infections that can lead to hospitalization.
Radiation therapy creates elevated superoxide radical levels, which are believed to be responsible for most of the side effects associated with this treatment, including OM. “The synthetic enzyme we designed and made mimics the function of the naturally occurring superoxide dismutase, an enzyme that converts superoxide to molecular oxygen and hydrogen peroxide,” says Riley, who is with Galera Therapeutics. “Hydrogen peroxide is very toxic to cancer cells but not to normal cells. Thus, we create two opportunities to improve radiation therapy: reducing toxicity for normal cells while increasing the toxicity to the cancerous ones.”
Designing and creating the synthetic superoxide dismutase was complex, and Riley’s team tried many variations of synthetic enzyme mimics before settling on GC4419. The research began decades ago when Riley worked at Monsanto/Searle. The molecules his team were working with had four chiral carbon centers, which meant there were a very large number of potential mimics.
“We had to figure out which isomer would work best and be the most ‘druggable,’” he reports. “Our current synthesis involves using a template to make the 15-membered macrocylic ring complex in a single GMP [Good Manufacturing Practice] step. It uses pyridine-2,6- dicarboxyaldehyde, manganese(II) chloride and a linear tetramine synthesized from S,S-1,2 diaminocyclohexane. It is an elegantly simple ‘one-pot’ synthesis that yields the desired molecule with more than 99.5 percent chemical purity.”
GC4419 successfully completed Phase 1 and 2 clinical trials, showing safety and efficacy in preventing SOM in head and neck cancer patients undergoing radiation therapy. If further clinical trials are successful and GC4419 gets FDA approval, Riley says, “there’s no reason it could not be used to prevent side effects from radiation treatment of other cancers. You can think of pancreatic cancer, for example, in which you might want to use high-dose radiation for locally advanced disease, but the pancreas is too close to other organs that cannot handle the side effects of radiation. We are currently studying GC4419’s anti-tumor effect in a Phase 1/2 clinical trial in pancreatic cancer at MD Anderson Cancer Center. If successful, this drug has the potential to change the management of radiation therapy since 70 percent of all solid tumors are treated with radiation.”
The Latest on: GC4419
via Google News
The Latest on: GC4419
- 58 Biggest Movers From Fridayon October 5, 2020 at 1:32 am
Gainers Xtant Medical Holdings, Inc. (NYSE: XTNT) shares climbed 91.4% to close at $1.57 on Friday after the company announced the closing of debt restructuring. American Renal Associates Holdings, ...
- Dosing is underway for Galera's lead asset in mid-stage COVID-19 studyon September 16, 2020 at 5:45 am
Galera Therapeutics (NASDAQ:GRTX) has dosed the first patient in a Phase 2 trial of lead candidate avasopasem manganese (GC4419) in critically ill hospitalized COVID-19 patients. The 50-subject ...
- Galera Therapeutics Announces Dosing of First Patient in a Randomized, Double-Blind Pilot Phase 2 Clinical Trial of GC4419 for COVID-19on September 16, 2020 at 5:17 am
GC4419 is an investigational, highly selective small molecule superoxide dismutase (SOD) mimetic designed to rapidly and selectively convert superoxide to hydrogen peroxide and oxygen.
- Galera Therapeutics Announces Dosing of First Patient in a Randomized, Double-Blind Pilot Phase 2 Clinical Trial of GC4419 for COVID-19on September 16, 2020 at 5:16 am
Company continues to advance its three ongoing trials evaluating the potential of GC4419 to address radiation toxicities and improve the anti-cancer effect of radiation “The unprecedented ...
- Galera Therapeutics Announces Dosing of First Patient in a Randomized, Double-Blind Pilot Phase 2 Clinical Trial of GC4419 for COVID-19 - MarketWatchon September 16, 2020 at 1:01 am
Trial to enroll up to 50 hospitalized adults critically ill with COVID-19 Company continues to advance its three ongoing trials evaluating the potential of GC4419 to address radiation toxicities and ...
- Company Updates Guidance for Topline Data Readout to ASTRO 2020on September 8, 2020 at 1:00 am
Today, Galera announced that data from its double-blind, placebo-controlled pilot Phase 1b/2a clinical trial of avasopasem manganese (GC4419) in combination with stereotactic body radiation ...
- Global Radiation-Induced Esophagitis Industry 2017-2030on August 28, 2020 at 10:13 am
The market report provides analysis regarding current treatment practices, emerging drugs like GC4419, potential therapies, market share of the individual therapies, and historical, current and ...
- A Study to Investigate the Effects of GC4419 on Radiation Induced Oral Mucositis in Patients With Head/Neck Canceron October 2, 2019 at 3:26 pm
If GC4419 is administered prior to intensity-modulated radiation therapy (IMRT) does it reduce the severity of radiation induced oral mucositis in patients who have been diagnosed with locally ...
via Bing News